|
N =251/group
| |
Group A (RA)
|
Group B (DM)
|
Group C (GP)
|
P, all three
|
P, A versus C
|
|---|
|
Medications
| | | | | | |
|
RA
|
MTX
|
126 (50%)
|
N/A
|
N/A
|
--
|
--
|
| |
HCQ
|
92 (37%)
|
N/A
|
N/A
|
--
|
--
|
| |
PDN
|
86 (34%)
|
N/A
|
N/A
|
--
|
--
|
| |
TNF
|
96 (38%)
|
N/A
|
N/A
|
--
|
--
|
|
DM
|
Insulin
|
N/A
|
100 (40%)
|
N/A
|
--
|
--
|
| |
Metformin
|
N/A
|
132 (53%)
|
N/A
|
--
|
--
|
|
NSAIDs
| |
74 (29%)
|
43 (17%)
|
51 (20%)
|
0.003
|
0.02
|
|
Anti-HTN
| |
66 (26%)
|
180 (72%)
|
86 (34%)
|
< 0.0001
|
0.052
|
|
Statin
| |
23 (9%)
|
162 (65%)
|
38 (15%)
|
< 0.0001
|
0.055
|
|
ASA
|
81 mg
|
22 (9%)
|
93 (37%)
|
33 (13%)
|
< 0.0001
|
0.12
|
| |
> 81 mg
|
5 (2%)
|
16 (6%)
|
6 (2%)
|
0.01
|
0.76
|
- Anti-HTN, antihypertensives; ASA, aspirin; DM, diabetes mellitus; GP, general population; HCQ, hydroxychloroquine; LEF, leflunomide; MTX, methotrexate; N/A, not applicable; NSAIDs, nonsteroidal antiinflammatory drugs; PDN, prednisone; RA, rheumatoid arthritis; TNF, anti-TNF agents.
